Released Sep 14, 2021, after the close
10-Q filed Sep 14, 2021, 45 days after period end · 0001654954-21-010079
Q3 2021 · 10-Q
Revenue$4.99M$4.99M −20.6% vs Q3 2020−1.1% vs Q2 2021
Net Income$2.28M$2.28M +228.7% vs Q3 2020+846.9% vs Q2 2021
EPS, diluted—
Gross Profit$1,255,062−32.3%
Operating Income$360,490−55.9%
Operating Cash Flow$441,724−63.8%
Free Cash Flowderived$434,614−64.1%
Margins · derived
Gross margin25.2%−4.4 pt vs Q3 2020
Operating margin7.2%−5.8 pt vs Q3 2020
Net margin45.6%+34.6 pt vs Q3 2020
What the release said
The release
Same quarter
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Revenue | $4.99M | $6.28M | $4.97M | $4.63M |
| Net Income | $2.28M | $692.11K | $431.16K | $730.63K |
| EPS Diluted | — | — | — | $0.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR